EUVIMEDEUVIMED entdecken
Crossref

Interleukin‐33 Promotes Interstitial Lung Disease in Idiopathic Inflammatory Myopathy Via ERK ‐Mediated Epithelial‐Mesenchymal Transition: ERK as a Potential Therapeutic Target

Jumei Yang, Wenjun Li, Jiarui Zhu, Xi Cui, Hui Chai, Qiyan Su, Jin Guo, Yingyue Feng, Zhuanhui Huang, Yun Lv, Sigong Zhang iD

Arthritis & Rheumatology · 2026

DOI: 10.1002/art.43453 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Jumei Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cuiying Biomedical Research Center, Lanzhou University Second Hospital, Lanzhou, China. Hauptthemen laut MEDLINE: Interleukin-33, Epithelial-Mesenchymal Transition, Lung Diseases, Interstitial, MAP Kinase Signaling System. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Natural Science Foundation of Gansu Province, National Natural Science Foundation of China, Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Interstitial lung disease (ILD) is the most common and prognostically severe complication of idiopathic inflammatory myopathy (IIM), for which targeted treatments remain limited. Based on previous findings that neutrophil extracellular traps (NETs) are key mediators in IIM‐ILD pathogenesis and given the established role of interleukin‐33 (IL‐33) in promoting NETosis, we hypothesized.

Methods

We integrated analyses of human IIM‐ILD samples with a myositis‐associated ILD (MAILD) mouse model employing IL‐33 knockout (KO) and reconstitution strategies. The ERK pathway was inhibited in vivo with U0126. In vitro, IL‐33 knockdown alveolar epithelial cells were challenged with NETs. Assessments included enzyme‐linked immunosorbent assay, immunohistochemistry and/or immunofluorescence, Western blot, and RNA sequencing.

Results

Serum IL‐33 levels were significantly elevated in patients with IIM‐ILD compared with healthy controls, with concurrent upregulation of IL‐33 in lung tissues. MAILD mice similarly showed increased IL‐33 expression, whereas IL‐33 KO mice exhibited attenuated lung inflammation, improved alveolar architecture, and decreased collagen deposition. Administration of exogenous IL‐33 restored ILD severity in IL‐33 KO mice to wild‐type levels. The levels of p‐ERK and epithelial‐mesenchymal transition (EMT) markers (E‐Ca and α‐smooth muscle actin) correlated with IL‐33 expression. U0126 reduced p‐ERK levels, suppressed EMT, and ameliorated both pulmonary inflammation and fibrosis. In vitro, NETs induced EMT and ERK activation in A549 cells, effects that were abolished upon IL‐33 silencing.

Conclusions

IL‐33 promotes IIM‐ILD progression by activating ERK‐mediate EMT, identifying the IL‐33/ERK signaling axis as a potential therapeutic target. These results provide mechanistic insight into IIM‐ILD pathogenesis and support translational strategies for precision intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-33Epithelial-Mesenchymal TransitionLung Diseases, InterstitialMAP Kinase Signaling SystemMyositisAnimalsHumansMiceMice, KnockoutDisease Models, AnimalExtracellular TrapsFemaleMaleLung

Substanzen

Interleukin-33IL33 protein, human

Autor:innen und Institutionen

  • Cuiying Biomedical Research Center, Lanzhou University Second Hospital, Lanzhou, China.
  • The Second Clinical Medical School, Lanzhou University, Lanzhou, China.
  • Department of Rheumatology and Immunology, Lanzhou University Second Hospital, Lanzhou, China.
  • Gansu Provincial Clinical Center for Rheumatology and Immunology, Lanzhou, China.

ORCID-Profile: Sigong Zhang

Förderung

  • Natural Science Foundation of Gansu Province
  • National Natural Science Foundation of China
  • Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital

Zitieren

APA

Yang, J., Li, W., Zhu, J., Cui, X., Chai, H., Su, Q., Guo, J., Feng, Y., Huang, Z., Lv, Y., & Zhang, S. (2026). Interleukin‐33 Promotes Interstitial Lung Disease in Idiopathic Inflammatory Myopathy Via ERK ‐Mediated Epithelial‐Mesenchymal Transition: ERK as a Potential Therapeutic Target. Arthritis & Rheumatology. https://doi.org/10.1002/art.43453

Vancouver

Yang J, Li W, Zhu J, Cui X, Chai H, Su Q, et al. Interleukin‐33 Promotes Interstitial Lung Disease in Idiopathic Inflammatory Myopathy Via ERK ‐Mediated Epithelial‐Mesenchymal Transition: ERK as a Potential Therapeutic Target. Arthritis & Rheumatology. 2026. doi:10.1002/art.43453

BibTeX
@article{Yang2026,
  author = {Yang, Jumei and Li, Wenjun and Zhu, Jiarui and Cui, Xi and Chai, Hui and Su, Qiyan and Guo, Jin and Feng, Yingyue and Huang, Zhuanhui and Lv, Yun and Zhang, Sigong},
  title = {Interleukin‐33 Promotes Interstitial Lung Disease in Idiopathic Inflammatory Myopathy Via ERK ‐Mediated Epithelial‐Mesenchymal Transition: ERK as a Potential Therapeutic Target},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  doi = {10.1002/art.43453}
}
Kostenlos starten →